PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly

NCT00532116 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2007-09-19

No results posted yet for this study

Summary

Evaluate the effect of age on the PK of two different doses of EMSAM.

Conditions

  • Healthy

Interventions

DRUG

EMSAM (Selegiline Transdermal System) 6mg

STS 6mg/24hr

DRUG

EMSAM (Selegiline Transdermal System) 12mg

EMSAm 12mg/24Hr

Sponsors & Collaborators

  • Somerset Pharmaceuticals

    lead INDUSTRY

Study Design

Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-04-30
Completion
2007-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00532116 on ClinicalTrials.gov